# The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer

> **NCT06738160** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 27 (estimated)

## Conditions studied

- NSCLC
- Stereotactic Body Radiation Therapy (SBRT)
- Immunotherapy

## Interventions

- **DRUG:** Narlumosbart

## Key facts

- **NCT ID:** NCT06738160
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-15
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06738160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06738160, "The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06738160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*